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ABSTRACT

Finding possible connections and solutions to help fight progression of diseases
is a major area of research. Genomics is a primary path of research in disease research.
Through the DNA sequence, possible connections to diseases have been found. However,
most methods for fixing issues within a DNA sequence are still out of reach. One potential
path is to investigate epigenetic modifications, such as DNA methylation. DNA methylation
occurs when a methyl group attached to cytosines on the DNA sequence. Statistical methods
can be used to identify sites or regions of significant differences in methylation levels
between groups ( e. g. disease vs. healthy). If these particular sites or regions can be linked
to diseases they could aid in better understanding the disease pathway and could potentially
be used to diagnose or treat the disease. With recent advancement in technology, tools
to measure and analyze methylation levels have become easier and are more accessible.
Thus, more and more researchers are investigating methylation to help identify possible
connections to diseases.
The statistical tools to analyze and find significantly different methylated sites or
regions have advanced. Since methylation levels have been shown to have correlation
among neighboring sites, meaningful differences in methylation levels commonly occur
over regions rather than individual sites. There are several statistical tools to test for
these regions, including three that are the focus of this thesis: Bumphunter, Probe Lasso,
and DMRcate. Each of these methods identifies regions that have significantly different
methylation levels in different ways. In this thesis, a thorough examination of each of these
methods is presented and all three methods are used to identify differentially methylated
regions (DMRs) between HIV positive women with and without squamons cell carcinoma
cervical cancer. The methods are compared to help better understand their impact of
identifying DMRs.
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1. INTRODUCTION

1.1. DNA METHYLATION
Finding the causes of human diseases is complex and has been studied for a very
long time. In the quest for potential answers, the field of genomics has begun to play an
important role in recent years [1]. Genomics is the field that involves analyzing and studying
genomes. Genomes are the complete set of the all the genetic material of an organism,
which is primarily orginized into chromosomes. These chromosomes are made up of
strands of DNA that contain genes, which code for functional units called proteins. Within
the DNA, there is an arrangement of four different types of nucleotides. These nucleotides
are thymine, cytosine, adenine, and guanine [1]. The arrangement of these four nucleotides
contain the information required to inform the cells of the human body to perform certain
functions. This transfer of information occurs when the coding units called genes under
go a process called transcription to messenger RNA and then translation to proteins, which
are functional units of the cell. Different genes are transcribed or "expressed" in different
tissues at different times depending on what functions are needed. However, occasionally
there might be an arrangement of the DNA sequence or an aberrant expression of genes that
are detrimental to the human body and can lead to formation of diseases such as cancers.
As a result, there is a desire to determine the locations of DNA sections that are associated
with diseases. If this knowledge could be found, then it could be used to better understand
the disease pathway and offer potential treatments. For diseases that are associated with
DNA sequence aberrations, it is often difficult to change the underlying genetic code. If
the issue is with gene expression, then mechanisms that can alter this process need to be
examined and explored.
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One type of epigenetic factor that might be a linked to diseases outside of the
formation of DNA, is DNA methylation. DNA methylation is a chemical addition to DNA
that occurs when a methyl (CH3) group is attached to the DNA sequence. DNA methylation
can affect how genes function and are expressed [2]. The common location for the methyl
groups to attach to DNA are at cytosine sites within cytosine-guanine dinucleotides (CpG)
[2]. This modification can be inherited when a cell undergoes division. However, this
chemical modification does not become a part of the DNA structure. An example of
DNA methylation can be seen in Figure 1.1. The original DNA sequence is not altered
by methylation, however methylation can determine if the neighboring location (gene) of
the DNA will be expressed. Methylation can be changed by environmental factors [2]. It
is for this reason that a set of twins may have identical DNA strands, but one of the twins
might develop a disease while the other does not. Due to the recent increase in technology
advancement, both testing for DNA methylation and treatments have become less expensive.
This has led to a major upswing in the amount of researchers investigating DNA methylation
as a possible avenue to treat major diseases.
DNA methylation can be linked with many different phenotypes, however it is
predominantly studied to determine how it is related to disease. A phenotype in this thesis
is a common characteristic that each individual in a identified group might possess. An
example of this could be a group of women who all show similar stages of the same
type of cancer. Many cancers have distinguishing methylation patterns that might be a
contributing factor or an indicator of the identified disease. Researchers would like to be
able to determine if the pattern is a cause or contributing factor for certain diseases or if
there are other reasons and the pattern is a result of the underlying causes. If the disease
is caused by methylation, then possible cures or treatments might be used that focus on the
aberrant methylation patterns [2]. Such a treatment could target the methyl groups that have
erroneously attached, or where the methylation was mistakenly lost. Thus, if the particular
locations with aberrant methylation patterns contributing to cancer could be identified, then
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Figure 1.1.
Illistration of DNA Methylation.
Found at htt ps
:
//commons.wikimedia.org/wiki/File : E pigenetic−mechanisms. j pg on October 2017.

methyl groups could potentially be removed or attached to counter a cancer’s progress.
There are two examples of potential drugs that have been created to counter cancers in such
a manner, Vidaza and Decitabine [3]. These two drugs are used against cancerous tumours
by the removal of methyl groups that are shutting-off genes that contribute to the tumour
suppression [3]. As the study of methylation progresses, potential future drugs might be
able to treat malignant tumours, but prevent them from ever forming.

1.2. TECHNOLOGY USED TO MEASURE DNA METHYLATION
To be able to study and determine possible connections of DNA methylation with
diseases, DNA samples from different individuals must be taken and DNA methylation
measured. One problem with finding such connections is that the locations of important
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CpG sites for testing are largely unknown at the start of a study. Thus the sites where
aberrant DNA methylation patterns occur could be anywhere within the genome. To make
sure that the important methyl groups are not missed, the entire genome must be tested for
methylation differences between healthy and diseased individuals. Different technologies
exist for measuring DNA methylation at a genome-wide level.
To test a whole genome for differential methylation, whole-genome bisulfite sequencing (WGBS) can be used to gather data about methylation levels at all CpG sites in
humans [2]. This process helps identify methylated sites by using the compound sodium
bisulfite which only affects unmethylated sites. The sodium bisulfite targets the unmethylated cytosine sites and changes them into uracils [2]. A uracil is a nucleotide that is used
in place of thymine in a strand of RNA [1]. The methylated sites however are unaffected
and remain the same. The bisulfite converted DNA is then sequenced via next generation
sequencing (NGS) techniques. This gives the ability to identify the possible methylated sites
by examining around 28 million CpG sites for any potential unchanged sites [2]. WGBS is
the most preferred method to gathering data about methylation in a single subject’s genome
since all potential sites of methylation would hopefully be identified. Unfortunately, WGBS
has a high cost per subject. Most studies prefer a large sample size of subjects; however
with a limited budget, the sample size when using WGBS is limited. This might mean that
the sample size is smaller than needed to attain reasonable statistical power to find true connections to the disease. Another reason WGBS is not widely used is due to the fact that data
collection and analysis methods take a high amount of training and technology that may not
be accessible to most researchers. Therefore, based on technology, training, and financial
cost factors, the WGBS approach is not the most feasible for many researchers/studies.
A more practical tool used to identify DNA methylation levels is a type of microarray
called the Illumina Infinium Bead chips. This type of microarray is a glass chip that has
probes that are short sets of nucleotides that correspond to CpG sites that are attached to
the chip to help measure methylation levels [1]. This method also uses sodium bisulfite;
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however, unlike WGBS, beadchips only target a subset of CpG sites and measure methylation
levels using predetermined probes on the microarray. Sodium bisulfite is used on DNA
samples in a similar method as WGBS. The sodium bisulfite targets unmethylated sites
and changes them to uracils while ignoring methylated sites. Then the samples then are
whole-genome amplified and broken into smaller sections with enzymatic fragmentation
[4]. These amplified fragments of the sample are then applied to the beadchip. These
fragments will interact with one of two types of probes: Infinium 1 (Type 1) and Infinium
2 (Type 2) [5].
The Type 1 or Infinium 1 probes contain what are known as two "beads." A bead is
made up of oligonucleotides, which are short synthetic DNA strands that contain sequences
complementary to those that surround the specific CpG sites of interest [6]. These are
important for being able to determine the methylation level at CpG sites. Type 1 probes
possess two separate beads that allows for detecting methylation levels with one bead and
unmethylation with the other bead at a determined site. This is accomplished by creating
a different oligonucleotide for each bead, one that will pair with the bisulfite converted
sequence when the site has been converted to a uracil (unmethylated) and one that will
pair when the site remains a cytosine (methylated) [4]. Once this pairing (or hybridization)
occurs, the information is reported as signals of light, the intesity of which provides a
measure of methylation and unmethylation. The light intensity is found after the beadchip is
fluorescently stained and intensity of stains are measured to determine levels of methylation
and unmethylation.
The other type of probe is the type 2 or Infinium 2. With this probe all the steps
are the same as type 1 except that when the sample is introduced to the probe, there is
only a single bead. This single bead has the capability to measure both methylation and
unmethylation levels at the site level. Type 2 probes create two signals for methylation
and unmethylation by allowing the correct nucleotide from the bisulfite converted DNA to
hybridize and be tagged with the specific dye color [7, 8]. The probe is also stained and
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intensities found in a similar way as type 1 probes. The intensity of green dye channel
represents the level of methylation and the intensity of the red dye channel represents the
level of unmethylation.
With the levels of intensities at each site, a numerical value called a β value can
be calculated to determine the percentage of methylation at a site and is found by the
following: β = (Max(M, 0))/(Max(M, 0) + Max(U, 0) + 100) [9] Through the beads, a
Max(M,0), which is the intensity of methylation at the site, can be found. The values for
Max(U,0), which is the intensity of unmethylation, can also be found [9]. The constant of
100 is used to avoid problematic β values in which both methylation and unmethylation
levels have low measurements [10]. The advantage of the type 2 probe is that more of
these probes can be put onto the array than type 1 probes [6]. This allows for more of
the gene sequence to be tested. The advantage of the type 1 probe is that this probe is
able to measure extremes of methylation and unmethylation intensities better than type 2
probes [7]. Together these two types of probes can be used throughout the beadchip to test
predetermined site locations. Since the beadchips are not able to cover the entire genome,
the results are less comprehensive than using WGBS. Since the probes are predetermined
and only a subset of the CpG sites, the beadchips are able to be produced easier than
WGBS, thereby reducing the cost of beadcips compared to WGBS[2]. Therefore, there is
a trade-off between accuracy and cost/use for WGBS and beadchips. However, since most
researchers/studies have a limited budget, the beadchips are often the preferred method.
The beadchips also provide an easier way to conduct testing on larger sample sizes, which
can aid in improving statistical power for testing.
Currently, there are three major types of beadchips. The first version was the
Human Methylation 27K Bead Chip (HM27). This version had 27,578 probes for testing
CpG sites and had the ability to test up to 12 samples per beadchip. The next version of
this microarray technology was the HM450 Bead Chip (450K). It also had the capability of
testing 12 samples per beadchip, however each beadchip contains 485,577 probes for testing
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corresponding CpG sites. The latest version as of 2016 is the EPIC Bead Chip (EPIC) which
has over 850,000 probes that are used to identify methylation levels at these sites [2]. As
the technology for microarrays has advanced, the number of probes has increased enabling
the researcher measure methylation at more potential CpG sites that may be connected to
diseases. As the number of probes on the beadchips increases, then the coverage across the
genome gets similar to WGBS. Currently, the most widely used microarray is the 450K,
however this will likely be replaced by EPIC in the near future.
The order of probes and the corresponding CpG sites that are tested follow a certain
pattern. It has been noted that certain segments of the genome contain a higher concentration
of CpG sites than expected by chance. These known high concentrations of CpG sites are
known as "CpG islands." CpG islands often occur near transcription factor start sites of genes
and thus the methylation status of them could affect expression of the nearby gene. The areas
neighboring the CpG islands where the concentration of CpGs starts to decrease (∼ 2kb
from CpG islands) are known as "CpG shores." Lastly the area of sequences neighboring
the CpG shores (∼ 4kb from CpG shores) where CpG sites are sparse can be known as
"CpG shelves [2]." The remaining areas of the sequence that are sparse in the number of
CpG sites are known as "CpG oceans." The names and definitions of these regions differ
slightly depending on the researcher. Since methylation occurs at CpG sites, the higher
concentration of CpG sites is of interest for testing. Thus the probes in the beadchips focus
on testing CpG islands and shores. For the 450K beadchips, the distribution of probes to
each region is the following: 32 % of probes for CpG islands, 23 % for CpG shores, 10 %
for CpG shelfs, and 36 % for CpG oceans [11]. As the technology improves, more probes
will be able to test the shelves and oceans.
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1.3. STATISTICAL METHODS FOR ANALYZING DNA METHYLATION DATA
When analyzing the data produced from DNA methylation microarrays, either single
sites or entire regions can be investigated. DNA methylation rarely occurs in isolation with
a lone methyl group being added to a cytosine site but rather often occurs in clusters
throughout the genome. Testing for differential methylation occurs when one compares
two groups of samples, such as treatment and control, and tries to determine if there is
a significant difference in the average levels of methylation at a certain location or set of
locations between the two groups. This testing can be conducted at either the individual
site level or the region level for the DNA. Methylation and thus meaningful differences in
methylation levels are more likely to occur over a region of the genome structure[2].
Methods have been developed to help identify these regions that are referred as
differently methylated regions (DMRs). These regions can be further investigated to determine if they are affecting the expression of nearby genes. When testing the regions,
DNA methylation is easier to identify when the regions range in size from several hundred
base pairs to several megabases. In the past, there was evidence to support that there is
correlation between adjacent sites’ methylation levels; meaning that if a site is methylated
then the neighboring sites are more likely to also be methylated [3]. Since regions are
more common than single site methylation, it is of interest to identify regions that have a
significant amount difference between average DNA methylation levels of the two examined
phenotypes, such as a disease group and a healthy group. Testing for DMRs enables the
possibility of finding links between methylation and the disease in question, which may lead
to potential diagnostic tools or treatments. The measurement of DNA methylation levels is
a continuous measurement. Any possible association between DNA methylation levels at
specific genomic locations and disease status is the goal.
A DMR consists of a set of CpG sites that have been grouped together based on
having a significant difference in their average methylation levels between groups. Figure 1.2
is an example of the methylation levels (β values) for a DMR. Notice there is a difference
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between the two distributions of site level methylation of the two groups of SCC and
Negative. DMRs can have a significant amount of variation in methylation levels between
sites in the region. This means that DNA methylation measurements can have measurement
error. Thus, when trying to identify DMRs, the analysis must take this into account. DNA
methylation is typically concentrated in regions throughout the genome. Thus, locations
of methylation will not be as dispersed throughout the genome. The benefit of this is that,
when analyzing the genome, less of it has to be examined when looking for methylation
than examining the entire DNA sequence.

Figure 1.2. Example of methylation levels for a DMR. Plot of Methylation level (β value)
versus genomic position. The two groups of interest (negative and SCC) are shown in
different colors.
1.3.1. Pre-processing. Other possible factors might have an effect on the formation
of a disease or DNA methylation, thus taking away the significance of a possible connection
between the disease and differentially methylated sites or regions. Therefore, these effects
or variables also need to be considered. Specifically, certain aspects of the data collection
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process can affect the data quality at some sites or in some samples and preforming filtering
steps can help ensure low quality data are removed. One issue can be attributed to the
probes that are used in measuring the data. This is usually called site level filtering. Probes
could be defective and not measuring the data correctly, so the final results could be skewed.
There are six different criteria that are used to determine if a probe or any data produced
from the probe need to be disregarded. The first involves filtering out probes that possess a
detection p-value that is less than 0.01. This is a good sign that the probe might be defective
and not correctly working. The proper action is to remove the probes that significantly failed
at detecting methylation levels. The next step is to remove any probe that in at least five
percent of the samples for each probe has less than 3 beads. If five percent or more of the
samples collectively have less than three beads at a particular probe, than the probe will be
removed. Third, remove any probes that are associated with non-CpG sites. Since DMRs
occur at CpG sites, probes from anywhere else will not have any pertinent information
about DMRs. Fourth, filter out probes that are associated with known single nucleotide
polymorphisms(SNPs). The reason is that SNPs can make the probes have difficulty in
identifying methylation at CpG sites and can cause change in color channels from the
probes [12]. The probes to be filtered out can be identified by using the database of General
Recommended Probes that was compiled by Zhou [12]. Fifth, probes that are categorized as
multi-hit should be removed. Multi-hit will be where the probe is methylated in all samples
[13]. This will defined by the Nordlund’s Genome Biology article[13]. Lastly, disregard
any probes located on the X or Y chromosome. The X and Y chromosome determines the
sex of the sample. If there is a difference in the sex of the samples then the male and female
beta values for the remaining chromosomes will be processed separately [5].
Another potential data quality issue is that particular samples could be outliers, thus
skewing the data. So after site level filtering is done, sample level filtering also needs to be
performed. A common approach to perform this filtering is to look at the beta distributions
for all of the samples and determine whether any of the distributions are significantly
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different than the remaining distributions. The data are then normalized to counter any bias
that might arise through the difference between type 1 and type 2 probes on the microarray.
The common method used to normalize the data is Beta Mixture Quantile Dilation (BMIQ)
[14]. The last significant cause of error is through a batch effect. This means samples for
a study have sub-groups that have correlation that is not attributed to the variables that are
being examined with the study. This is usually detected by the presence of extreme outliers
that are not representative of the population that the samples are supposed to represent. An
important example of this is when samples for the same study were collected at different
processing dates. Thus, a possible sub-group might form that has a correlation that could
be attributed to a different person collecting the samples or the samples being taken from
a different environment [3]. It is important to try to reduce possible batch effects with a
proper experimental design. However, if batch effect can not be removed then a correction
on the data needs to be done. For this thesis, there were no known batch effects, thus no
correction on the data was necessary.
1.3.2. Methods for DMR Testing. Many methods for identifying significant DMRs
in DNA microarray data use different types of smoothing methods as one of the steps in
their testing framework. The method of smoothing involves finding a curve that highlights
the main patterns in a set of data that does not have constraints and is not heavily influenced
by individual data points. There can be different methods to obtain such a smoothed curve.
One method, called local regression or Loess (or Lowess) involves gathering points that will
be used in the curve fitting by examining several neighborhoods within the data. The data
will be divided into sections of points that are located closely in terms of their input values
and be grouped into neighborhoods. An example for this thesis would be grouping methylation levels together based on their CpG site locations being close together. All methods
that use neighborhoods use a bandwidth or smoothing parameter that the researcher can set
to determine the size of each neighborhood that will be used with the method. Within these
neighborhoods, a polynomial regression fit (typically linear or quadratic) is obtained and
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then the fitted values from the regression are gathered for the overall Loess smoothing. In
the polynomial fitting, the weighted least squares approach is used so that data points within
each neighborhood that are further away from the center are given less weight than those
near the center, as determined by a specified weight function. The tricube weight function
is commonly used. To combat the issue of weighting some values less, a new neighborhood
is constructed in order for the regression fits to be centered around the previously less
weighted values. The resulting fitted values are once again collected and the values are
given weights. The regression fitting is repeated for multiple neighborhoods, potentially
up to the total number of data points. To make the procedure more robust to outliers, the
regression fit in each neighborhood can be repeated a determined number of times. In each
fitting, the weights can be updated according to the size of residuals in the previous fitting
so that points with large residuals receive less weight [15].
Another option for smoothing is the method of running medians. Smoothing is done
by obtaining a collection of median output values calculated from subsets of the data. The
medians are determined from a subset of output values that are grouped based on similarity
of their input values. For example, median values would be found from the methylation
values that come from CpG sites that are close to each other. These medians of output
values are found by sequentially defining subsets of the data based on their adjacent input
values throughout the remaining data (i.e., moving windows). The resulting medians are
then used as the smoothed values [15].
The last major smoothing type used within this thesis is the Gaussian Kernel smoothing method. Kernel smoothing methods provide weighted averages of the output values (e.
g. methylation levels) located in a neighborhood based on similar input values (e. g. CpG
site location). The bandwidth λ defines the width of the neighborhood and the weighted
averages are calculated using a moving window. The major key for this method is the use of
weights which are defined by a "kernel" function. Weights help determine the importance
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that needs to be given to certain surrounding CpG sites when determining the smoothed
value. The methods used in this thesis utilize Gaussian Kernel Weights, which are defined
as the following:
Ki j = exp((−[xi − x j ]2 )/2σ 2 ) [16]
This is applied to the xi and x j CpG sites where σ is the kernel scale factor, which should be
proportional to the bandwidth λ. Thus σ is set to be σ = λ/C, where λ and C are pre-chosen
[16]. This is then used at each potential xi CpG site to help produce the following three
equations:
Í
SKY (i) = nj=1 Ki j ∗ Yj
Í
SK (i) = nj=1 Ki j
Í
SKK (i) = nj=1 (Ki j )2 [16]
These summations are calculated with the kernels for all the xi CpG sites on a chromosome
for methylation levels or test statistics. The SKY (i) summation represents the smoothed
model, whereas the other two summations are used in other aspects of the DMR testing
method [16].
In addition to smoothing, another factor important to DMR testing is imposing some
type of control over the amount of false positives (Type 1 errors) that could occur across the
multiple tests conducted. At the site level, hundreds of thousands of hypothesis tests could
be conducted, one for each CpG site. Although region level testing reduces the number
of tests, there are still multiple tests and many methods rely on site level significance. In
many genomic studies, it is common to control the false discovery rate (FDR). The FDR is
defined as:
F DR = E(V/R | R > 0)Pr(R > 0) [9]
Let "R" be the number of differentially methylated sites detected (i.e. discoveries). This
number "R" can be broken down into the number of correctly identified differentially
methylated sites ("S"), and the number of falsely chosen differentially methylated sites
("V") [9]. Thus, V/R represents the proportion of false discoveries which is conditioned
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on the number of discoveries being greater than zero. Through this, the testing error rate
will be controlled. Specifically, Benjamini and Hochberg introduced a method to control
the FDR at level α [17]. An adjusted p-value can be calculated from this method and tests
with an adjusted p-value less than α will reject the null hypothesis.
To test for DMRs, three main methods are considered in this thesis: Bumphunter,
Probe Lasso, and DMRcate. These are described in detail below. Bumphunter is a statistical
method that uses smoothing at the site level to help detect potential DMRs. Bump hunter
uses linear regression modeling and smoothing techniques on the data to help determine
differentially methylated regions that are considered significant [3]. The first step is to fit
the following statistical model:

Yi j = µ(t j ) + β(t j )Xi +

p
Õ
k=1

γ k (t j )Zi, j +

q
Õ

al, j Wi,l + εi, j

(1.1)

l=1

[3]
With DNA methylation data, the j th CpG site from the genome for individual i, will have a
methylation level of Yi j . This model will be fit from linear modeling the data through the
use of a framework similar to limma, which is commonly used in other areas of genomics.
The Yi j will be a transformed β value from the beadchip. The transformation will be:
M = log2 (β/(1 − β)) [9]
This transformation is done so that the Yi j values are not bounded between zero to one like
β values. At the j th CpG site of the genome, t j represents the CpG site will be location
within the genome. The average DNA methylation at the CpG sites of the control group
(baseline) is represented by µ(t j ). The Xi term denotes the phenotype group (e.g. disease
or healthy) within which individual i falls. β(t j ) represents a possible association between
Xi and Yi j at location t j . Any p number of confounders that might exist will be shown with
Z’s. The effects that confounder k has at t j is represented with γ k (t j ). Any confounders
or batch effects that are not able to be measured will be shown with W. The amount of
effect of the l th unmeasured confounder at t j will be represented with al, j . For data used
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within this thesis, there will be no Z’s or W’s so these terms can be removed from the
model. Any unexplained variability or error will be denoted with the error term εi, j , with
variances depending on the location σ 2 (t j ). The primary interest is to identify locations in
the genome, shown with t j , where β(t j ) does not equal zero (i.e. "bumps"), thus indicating
that there is a possible connection between a phenotype such as disease status and the
location of methylation. These sites will be grouped into regions of interest that might be
DMRs. These are portrayed with Rn, n = 1, · · · , N where β(t j ) , 0 for all t ∈ Rn [3].
The goal of Bumphunter is to identify these regions or "bumps" across the genome
and this is accomplished by a set of four steps. First, β(t j ) must be estimated for each t j .
These values of β(t j ) are then used to help create a smoothing function, β(t). The smoothing
within this thesis will be done with the Loess method. This smoothing function will be used
to help determine any anomalies or bumps in the function to help predict possible Rn or
the possible regions where there might be significant differentially methylation occurring.
Rn will be made up of smoothed β values that are either more than or less than a chosen
threshold value K. The area of each region is then calculated as a metric to indicate the
strength of differential methylation in the region. Permutation techniques are then employed
to assign statistical uncertainty to each of the previous regions that were identified with the
smooth function [3]. To do this, the phenotype variable Xi is permuted and the bumphunter
process of linear modeling, obtaining smoothed βs, and finding areas for regions of interest
is repeated a large number of times (e.g. B = 1000). The areas of the regions that are
produced in the B permutations are considered null areas and can provide a null distribution
for the region areas. This distribution can then be used to find a p-value for each potential
region. Multiple p-values are going to be calculated, one for each region. This causes
a problem when multiple hypothesis are conducted. To combat this, false discovery rate
(FDR) will be controlled at level α using the Benjamini and Hochberg approach [17]. The
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resulting bumps deemed significant will be considered significant DMRs. Note that an
alternative bootstrap method may be used, especially when the model contains batch effects
to improve computational efficiency.
Probe Lasso is a method that can offset potential bias which might occur from the
unequal concentrations of CpG sites represented by probes in different types of genomic
regions (e.g. CpG islands, open sea). It does this by controlling a window size for which
the possible DMRs will be defined against the local density of CpG sites with the probes
present on the array. A "flexible window" or "lasso" is "thrown" around identified CpG sites
with a probe that exhibit significant difference in methylation. The sites that are deemed
to be significant are determined by site level testing for significant differential methylation
levels based on the reported β values. A linear model similar to that of Bumphunter as
in equation (1.1) without the batch or confounding effects is fit using a method called
limma [18]. The limma approach differs from Bumphunter in the way the error variance is
estimated. Limma uses an empirical Bayes approach to shrink individual site level variance
to a common pooled estimate. Site level significance is established by testing whether
β(t j ) = 0. The lassos have a center located at the probe and a set mean radius on either
side of the probe. The lasso will be able to expand larger in regions that are more sparse
with potential sites (e.g. the open sea). In high concentration of CpG sites, the lassos will
be shrunk (e.g. CpG islands). The average will be decided by the researcher. Any sites
that fall within this lasso that show significance in being differentially methylated are then
considered part of a potential DMR, with the hope of meeting the minimum number of sites
which are within the lasso’s boundary to be considered a DMR. A site within the lasso is
deemed significant using the same limma approach that was used to determine significance
for the sites at the centers of the lassos. If there are overlaps of lassos, then the lassos and
the probes within the adjacent lassos are combined together to make a potentially larger
DMR. The amount of separation between lassos to be considered combined together is a
parameter that will be set by the researcher. The minimum number of sites within each
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lasso that needed to be defined as a DMR and radius of the lassos are two parameters for
the Probe Lasso test that are important in determining DMRs [19]. The p-value for each
DMR is found by using Stouffer’s method to weight site level p-values and calculate a
combined p-value for the region [20]. Stouffer’s method is used because neighboring sites
have been shown to be correlated with each other in terms of having similar methylation
levels. Therefore, Stouffer’s method uses weights to account for the distance between sites,
which is based on a correlation matrix of the normalized beta values from the data within
each DMR. With this matrix, sites that are uncorrelated with other sites are weighted more
heavily, while sites that show correlation in the methylation levels are down weighted. After
this, the weighted p-values of sites can be combined to obtain a p-value of the DMR itself.
Due to the multiple p-values being found at the site level, a multiple hypothesis type 1 error
rate can occur when finding the DMR p-value [19]. The false discovery rate for testing
multiple DMRs is controlled at level α using the Benjamini and Hochberg approach [17].
The final method considered for DMR testing in this thesis is DMRcate. DMRcate
finds test statistics for identifying differential methylation at each of the CpG sites similar
to Bumphunter and Probe Lasso. This is done through the use of the limma framework to
conduct linear modeling to obtain a test statistic, t, for testing the difference in methylation
at the site level. This test statistic is based on a test for β(t j ) = 0 as in equation (1.1)
described in Bumphunter using M values and a variance shrinkage estimation procedure.
However, in this method, the direction of the difference of methylation between the two
compared groups does not matter. At a site, a cancerous group’s methylation level being
higher than the noncancerous group is not important. The only important information for
this test is the magnitude between the methylation levels in the two groups. Thus the test
statistic is squared, t 2 , to obtain magnitude not direction. Gaussian Smoothing, as discussed
earlier, is then applied with the new test statistics. The matrix that is used to smooth the
model is determined with a known bandwidth parameter of λ [16]. This parameter is
also later used to determine which sites should be clustered to form significant DMRs.
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The new values for the test statistics obtained from smoothing are then modeled using
the Satterthwaite method [21]. Satterthwaite models the smoothed statistics SKY (i) by a
scaled χ2 distribution where it’s parameters are determined with SK (i) and SKK (i) that were
obtained from the Gaussian Smoothing. The P-values are then found from this model by
utilizing a χ2 distribution and the p-values produced are then adjusted with the Benjamini
and Hochberg correction to control the FDR. Then sites or probes that are found to be
significant with their adjusted p-values are grouped into possible DMRs. The grouping of
significant sites is controlled with the bandwidth value λ that was used with the Gaussian
Smoothing earlier [16]. This allows this method to use the minimum adjusted p-value in
the regions to be a representative p-value of the entire region. A significant parameter for
DMRcate is the chosen false discovery rate (FDR). This determines which sites will be
deemed to be significant and potentially be clustered into DMRs.

1.4. SUMMARY
When determining if there is a possible connection between DNA methylation and
developing diseases, the 450K microarray is commonly used to collect information for
large scale studies with many samples. Typically at least two different phenotypes will be
investigated to determine their association with DNA methylation patterns. An example
could be a group of individuals that have tested positive and negative in possessing a type of
cancer. When analyzing the resulting data from the microarrays, filtering and normalizing
the data to counter any error that might result from the samples or probes is first performed.
Once this is done, either site or region level testing is done to determine locations where there
is a significant difference in methylation levels between the two or more groups represented
in the samples.
Concentrations of identified CpG sites that exhibit significant differential methylation can be clustered and tested for being differentially methylated regions (DMRs). To
determine if there are any DMRs and where they might be, numerous testing methods can be
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used on the gathered data using statistical techniques. In this thesis, the Bumphunter, Probe
Lasso, and DMRcate methods are used and compared in their ability to identify significant
DMRs in the data.
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2. EVALUATING REGION-LEVEL TESTS FOR 450K METHYLATION DATA

2.1. DATA SET
The DNA methylation data that will be examined in this thesis was obtained from
450K microarrays by Fred Hutchinson Cancer Research Center in 2013. Data were obtained
from a group of either Kenyan or Senegalese women who are HIV positive and have various
stages of pre-cancerous cervical lesions. There were 5 types of groups among the women
that were tested: three different types of cervical pre-cancerous lesions of CIS, CIN2,
CIN3, a group with Squamous Cell Carcinoma (SCC), and a group of women without any
pre-cancerous cervical lesions (Negative). It is of interest to determine whether there are
any significant differences in methylation levels among the different cancer stages. Within
this thesis, the SCC and negative group will be used and examined. The negative group is
deemed the ‘control’ and the SCC group is the ‘test’ group to help determine if there are
possible links between methylation levels in certain regions of the genome and the existence
of the pre-cancerous lesions. There are 5 women with SCC cervical cancer and 8 women
with no pre-cancerous lesions.

2.2. ANALYSIS METHODS WITH R/BIOCONDUCTOR SOFTWARE
To process and analyze the data obtained from DNA methylation microarrays, the
statistical program R is often used since many researchers develop packages for method
implementation and annotation packages are available that can be easily integrated into
results. In R, a suite of packages for analyzing genomic data is available in a software called
Bioconductor. Packages within Bioconductor can be used to test for differential DNA
methylation in either regions or single sites in diverse ways. The primary package used for
processing the DNA methylation microarray data is "minfi". With this package, methylation
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levels at individual sites can be calculated and potentially significant methylation level
differences at CpG sites can be identified. Also, this package is the primary package that
enables the site and sample level filtration that was discussed in chapter 1. In conjunction
with using "minfi" for site level methylation analysis, numerous packages can be used to
help identify possible DMRs such as the following: "Bumphunter", "Probe Lasso", and
"DMRcate." There are other methods and packages that can help identify possible DMRs
however, the previous three will be the ones examined within this thesis [3].
Recently, a package known as "The Chip Analysis Methylation Pipeline" (ChAMP)
was developed that combined several processing and analysis methods into a single package.
ChAMP is a pipeline that lets the user pre-process data from 450K or EPIC microarrays,
normalize the data, conduct a Batch effect correction if possible, detect possible differential
methylated positions (DMP), and detect possible differentially methylated regions (DMRs)
[22]. This pipeline as of July 25, 2017, lets the user conduct DMR testing with Bumphunter,
DMRcate, and Probe Lasso [3, 16, 19].
With each of these three methods for region level testing, various parameters for
the tests can be changed and adjusted through the common ‘champ.DMR()’ function in
the ChAMP package. Several parameters are shared between all three tests including the
minimum number of probes that are required to from a region and the minimal p-value to
determine if a DMR is defined as significant. However, some parameters are specific to
the individual methods. Some important parameters solely for the Bumphunter test include
maximum length of DMR and the integer value for the number of permutations used in the
null distribution for the test. For DMRcate, important parameters include: the maximum
distance between SNP and CpG probes to be taken out of data, the lambda value for the
bandwidth used in the Gaussian kernel for smoothing, and the scaling factor used for the
bandwidth. Probe Lasso parameters include the minimum radius of each lasso used, the
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minimum distance between neighboring DMRs, minimum size of DMRs, and minimum
significant value for probes to be counted with the DMR. Each of these parameters can be
changed and fine-tuned to better detect possible DMRs [22].
The ChAMP package also has a default pipeline that can automatically call distinct
functions involved in analyzing the data, including preprocessing, normalization, finding
DMPs, clustering, block finding, and finding DMRs. A general overview of the various
aspects of analyzing 450K data is given below.
The data are first loaded and interpreted from .idat files that are obtained from
the 450K microarray to determine the methylation levels at all CpG sites by using the
‘champ.load()’ command [5, 12, 23]. In addition to determining methylation levels, this
function also filters out any sites with probes that have been deemed to fail, probes that
with less than 3 beads in less than five percent of the samples, any probes that do not
contain any CpG sites, any probes that can be related to SNPs, any multi-hit probes, and
any probes with data from Chromosome X or Y. This is done through the use of the
package of "minfi." To determine if there are any quality control issues with the samples
the function of ‘champ.qc()’ can be utilized. This will help create several figures that can
be used to determine if any of the subjects should be removed. Experimental error, such
as from differing probe types, needs to be corrected by normalization of the data using the
‘champ.norm()’ function [14]. This is done through an option of four types normalization
methods, "BMIQ," "SWAN," "FunctionalNormalize," and "PBC" [8, 14, 23, 24]. The
default setting and the method used in this thesis was the BMIQ function. The advantage
that BMIQ has over the other three methods is that it is able to run in parallel. This means
that if the computer can support more cores being run parallel to each other, then the faster
BMIQ will normalize the data [14].
ChAMP also has the ability through the use of the "minfi" package to analyze
site level differential methylation. This is done with the ChAMP package function of
‘champ.DMP()’ [25, 26]. Individual CpG sites are examined for differential methylation
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rather than testing for DMRs. Some additional options include identifying and counteracting batch effects with the ‘champ.runCombat()’ function and identifying blocks with the
ChAMP function of ‘champ.Block()’. However, for this thesis the only ChAMP functions
used were the ‘champ.load,’ ‘champ.qc,’ ‘champ.norm,’ and ‘champ.dmr.’ Through the
use of these functions, the Bumphunter, Probe Lasso, and DMRcate tests can be utilized.
Although the other functions were not used, ChAMP does give a flexible overall package
that lets the user analyze both 450K and EPIC microarrays in multiple ways. It also lets
the user produce plots of the various results, many of which are connected to the genomic
annotation to aid in interpreting results [22].

2.3. EVALUATING DIFFERENT PARAMETERS
Within the ChAMP package there are several values that can be changed prior to
evaluating DMRs within the ‘champ.DMR()’ function. For simplicity, these values that are
input to the function are called parameters. Depending on whether the test is Bumphunter,
Probe Lasso, or DMRcate, the parameters can vary. Firstly, there are 7 parameters that exist
across all three tests. They are beta, pheno, arraytype, method, minProbes, adjPvalDmr, and
cores. Beta is a matrix of normalized beta values representing the methylation level for each
CpG site. Pheno represents the phenotype or factor to be analyzed. In the data used in this
thesis, the phenotype is the cervical cancer status(Control/Negative or Cancerous/SCC).
Arraytype lets the user determine what type of technology was used to collect the data. The
two options are 450K or EPIC with the 450K being used here. Method enables the choice
of Bumphunter, Probe Lasso, or DMRcate. MinProbes decides the minimium amount
of probes needed for determining what will defined as clusters for potential DMRs. For
example, if the minProbes is set to 7, then there will not be any DMRs that would have
6 or less probes in their range. AdjPvalDmr lets the user choose a p-value threshold to
determine if a DMR is found to be significant. The cores setting helps decrease processing
time by running the function in parallel[22].

24
The parameters that are solely used in Bumphunter are maxGap, cutoff, pickCutoff,
smooth, smoothFunction, useWeights, permutations, B, and nullMethod. MaxGap is the
largest possible length between sites to be considered part of the same DMR. Cutoff
determines what regions or bounds for the genome should be tested for DMRs. PickCutoff
is the value used with the Bumphunter algorithm as a cutoff value with its permutation
process. Smooth determines if the SmoothFunction from ChAMP will be used to smooth
the data. There are two options for smoothing types in the SmoothFunction: loessByCluster
or runmedByCluster. The loessByCluster denotes the loess smoothing method, while
runmedByCluster denotes running median smoothing method [27]. The parameter of
UseWeights affects the loessByCluster by being able to determine the weight functions
that it will use. If runmedBycluster was used with SmoothFunction, then UseWeights is
ignored. The method of creating the null distribution has a choice between bootstrap and
permutation and is chosen with the parameter nullMethod. Permutations allows the user
to create a null distribution by using a chosen matrix that will help randomize the data.
However, this parameter is only used if Bootstrap is not used to randomize the data. When
creating the null distribution using the bootstrap, the parameter that determines the number
of times that resampling occurs with the data is the B[3, 22].
The parameters for only Probe Lasso are meanLassoRadius, minDmrSep, minDmrsize, adjPvalProbe, Rplot, PDFplot, and resultsDir. MeanLassoRadius determines that each
probe will have a lasso that is a chosen radius. MinDmrSep allows the user to decide for
different DMRs, what the minimum distance will be that separates them from each other.
MinDmrSize decides for all possible DMRs what the minimum size they must be for the
DMRs to be considered significant. This means that the length of the DMR must be at
least some chosen value of minDmrSize. AdjPvalProbe decides for each probe, the p-value
threshold used to consider the probe to be part of a potential DMR. PDFplot gives the option
of creating a plot of the DMRs that were created with the lassos. The ResultsDir parameter
indicates where to store the final results on the user’s computer [19, 22].
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Finally, the unique parameters for DMRcate are rmSNPCH, fdr, dist, mafcut,
lambda, and C. RmSNPCH gives the option of filtering the Beta (or M values) that are
reported for the probes by distance from SNPs. Fdr determines the value for the false
discovery rate. Dist allows the user to determine the largest possible distance between
SNPs and CpGs for filtering. Mafcut determines if probes can be removed from the data by
determining the smallest value for the allele frequency of each probe. Lambda decides the
Gaussian kernel bandwidth to be used in conjunction with the smooth-function estimation
that is used in DMRcate to help determine DMRs. For the Gaassian kernel, the parameter
that determines what factor the bandwidth should be scaled at is C [16, 22].

2.4. SUMMARY
In this thesis, DMRs will first be identified using default parameters of each method.
Results will be compared by investigating the number of DMRs identified by each method
and summarizing various aspects of the identified DMRs. Similarity of DMRs identified
between the methods will be examined by calculating the average percentage of overlap
in genomic area covered by DMRs commonly identified by the methods. Further analysis
will be conducted to better understand how certain parameters affect the results and attempt
to find settings where all methods identified the same number of DMRs. Although it
is uunknown where the true DMRs are located, the goal of this thesis is to provide an
illustration of how the three methods can be used to find DMRs and provide a comparison
of the results in real data. Investigating the different parameter settings and comparing the
three methods provides insights into similarities and differences between the methods and
their results.
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3. RESULTS

3.1. LOADING AND FILTERING
When the .idat files for the data are first loaded into ChAMP, there are a subset of
485,512 probes that have information about methylation and unmethylation for each sample.
The filtration process then removes certain probes based on criteria described previously. In
the first step, any probes that have a p-value of detection of less than 0.01 were removed. For
these data, this resulted in 2642 probes being removed. Next, any probes with beadcounts
that are less than 3 in at least 5 percent of the samples were removed. This amounted to
4537 probes being filtered out. Then only probes that have association with CpG sites were
to be used with any testing for DMRs. The number of probes taken away for this filtration
was 2999. The fourth filtration involved removal of any probes that have SNP association,
resulting in 49,692 probes being removed from the data. The fifth step eliminated multi-hit
probes. Thus, 7059 probes were taken out of the data. Lastly, 10,106 probes were removed
due to being located on either the X or Y chromosomes. The final number of site level
probes that used in the DMR testing was 408,477.
For sample level filtration, a raw density plot was produced and can be seen in Figure
3.1. There were no noticeable samples that appeared as outliers. Thus, all 13 samples were
used for the DMR testing.

3.2. PARAMETER SETTINGS FOR IDENTIFYING DMRS
All three methods (Bumphunter, Probe Lasso, and DMRcate) were first implemented
to identify DMRs under their default parameter settings and these results are compared.
Then an effort was made to better understand how the parameter settings affect the results
and compare the methods when a similar number of DMRs are identified for all methods.
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Density plot of raw data (408477 probes)
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Figure 3.1. Raw Density Plot of Beta values for all 13 samples. Samples in different
phenotype groups (Negative vs SCC) are labeled in different colors.

To accomplish this, parameters were altered for two of the methods to achieve the same
numbers of DMRs as identified in the default values of the third method. This procedure
was performed using the defaults for each of the three methods. Table 3.1 summarizes
the analyses that were conducted and introduces notation that will be used throughout the
remainder of this chapter. Tables 3.2, 3.3, and 3.4 provide the values of the parameters used
in Bumphunter, Probe Lasso, and DMRcate respectively for each analyses. With all three
methods, an attempt was made to keep all common parameters (minprobes, adjPvalDMR)
that the three methods share the same. This was done so that a better comparison between
methods could be made. The only exception to this was the parameter that determines the
number of cores when running DMRcate. In order for DMRcate to be able to run, the
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number of cores must be set to 1 instead of the default of 3. If kept at 3, then the test was
not able to run. However, this should only affect the computational efficiency but not the
results.
To change the number of DMRs identified by a specific method, parameters unique
to the method type were changed. In Bumphunter and DMRcate only a single parameter
was changed to find similar numbers of DMRs as defaults of the other methods. In
Bumphunter, the maxGap was changed as highlighted in Table 3.2. As the maxGap
parameter increases, the number of DMRs identified increases. In DMRcate, the FDR was
changed as is highlighted in Table 3.4. From the results, with an increase to FDR cutoff
that declares individual sites significant, there was a corresponding increase in the number
of DMRs identified. Probe Lasso on the other hand, required changing two parameters,
meanLassoRadius and adjPvalProbe as highlighted in Table 3.3. The need to change two
parameters was due to the need to get similar number of DMRs as the other two methods
and this was accomplished with the combination of both parameters rather than a single
parameter change. Increasing both the mean Lasso Radius and adj Pval probe seemed to
increase the number of DMRs identified.
There were certain pieces of information about the resulting DMRs with each method
that are important to note. The important pieces of information are the number of DMRs
identified with each method, which Chromosome each DMR is located on, and the width of
each DMR. All three of these were reported in the results of each test. Another important
piece of information was the number of CpGs in each DMR. However, this was only reported
with DMRcate. Thus, to help find these values for both Bumphunter and Probe Lasso, an
annotation table with the location of all CpGs known as "Illumina450ProbeVariants.db" was
used in conjunction with the results of the DMRs from both Bumphunter and Probe Lasso
[28]. With each DMR identified, a function was made to determine if any CpG sites from
the annotation table were located within the bounds of the DMR. The number of CpGs in
the DMRs might not be exactly correct since the annotation table includes all CpG prior to
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Table 3.1. Notation for each of the nine analyses conducted
Notation
BMP
PL
DC
BMP-PL

BMP-DC

PL-BMP

PL-DC

DC-BMP

DC-PL

Description
Bumphunter with default parameters
Probe Lasso with default parameters
DMRcate with default parameters
Bumphunter with changed parameters
to get a similar number of DMRs as
Probe Lasso default
Bumphunter with changed parameters
to get a similar number of DMRs as
DMRcate default
Probe Lasso with changed parameters
to get a similar number of DMRs as
Bumphunter default
Probe Lasso with changed parameters
to get a similar number of DMRs as
DMRcate default
DMRcate with changed parameters
to get a similar number of DMRs as
Bumphunter default
DMRcate with changed parameters
to get a similar number of DMRs as
Probe Lasso default

Table 3.2. Bumphunter Parameters
Method
minProbes
adjPvalDmr
cores
maxGap
cutoff
pickCutoff
smooth
smoothFunction
useWeights
permutations
B
nullMethod
Number of DMRs

BMP
7
0.05
3
300
NULL
TRUE
TRUE
loessByCluster
FALSE
NULL
250
bootstrap
277

BMP-PL
7
0.05
3
19
NULL
TRUE
TRUE
loessByCluster
FALSE
NULL
250
bootstrap
1

BMP-DC
7
0.05
3
570
NULL
TRUE
TRUE
loessByCluster
FALSE
NULL
250
bootstrap
494
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Table 3.3. Probe Lasso Parameters
Method
minProbes
adjPvalDmr
cores
meanLassoRadius
minDmrSep
minDmrSize
adjPvalProbe
Number of DMRs

PL-BMP
7
0.05
3
1180
1000
50
0.3
277

PL
7
0.05
3
375
1000
50
0.05
1

PL-DC
7
0.05
3
1770
1000
50
0.3
490

Table 3.4. DMRcate Default Parameters
Method
minProbes
adjPvalDmr
cores
rmSNPCH
fdr
dist
mafcut
lambda
C
Number of DMRs

DC-BMP
7
0.05
1
T
0.0329
2
0.05
1000
2
276

DC-PL
7
0.05
1
T
0.001
2
0.05
1000
2
1

DC
7
0.05
1
T
0.05
2
0.05
1000
2
492

filtering. Thus, extra CpGs could be included. However, this should give an idea about what
the numbers of CpGs in each DMR might be. The final metric important for comparing
methods is how much the DMRs from each test overlap with DMRs identified with other
methods. That is, the percentage of overlap in the genomic area covered by DMRs identified
by two methods is calculated. To be able to find this, the package known as "IRanges" was
used [29]."
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3.3. COMPARING BMP, PL, DC
The first comparison was made when Bumphunter, Probe Lasso, and DMRcate were
kept at their default parameters, except for the number of cores changed to 1 for DC. As
seen in Tables 3.5, 3.6, and 3.7, BMP was able to identify 277 DMRs, PL was able to find
1, and DC found 492. As seen in Table 3.5, both BMP and DC identify DMRs that have
similar average and standard deviation of widths of DMRs, while PL’s width is smaller. A
histogram of the widths of DMRs is given in Figure 3.2. It can be seen that DC found a
higher frequency of longer DMRs that BMP, even though the averages are similar. From
Table 3.6 and Figure 3.3, BMP and DC had similar numbers of the mode and standard
deviation of the Chromosome number, while once again PL was different from the other
two. It is interesting to note that in Table 3.7 and Figure 3.4, PL appears to have more than
twice as many CpGs in its shorter DMR than either of the other two tests. Also from Table
3.8, 233 of the DMRs exhibited overlap between BMP and DC. Of these, a high average of
overlap exists at 94.8 % when comparing the DMRs found between BMP and DC. Figure
3.5 reveals that the majority of these 233 exhibited over 90% overlap. Also notable is that
the single overlap between the DMR from PL was identified with both BMP or DC.
Table 3.5. Width of DMRs with BMP, PL, and DC
Method
BMP
PL
DC

Number
of DMRs
277
1
492

Average
Width of DMRs
1175.018
654
1363.980

Standard Deviation
of Width of DMRs
634.300
0
769.245

Table 3.6. Chromosome of DMRs with BMP, PL, and DC
Method
BMP
PL
DC

Number
of DMRs
277
1
492

Mode of
Chromosomes of DMRs
1.000
6
1.000

Standard Deviation
of Chromosome of DMRs
5.832
0
6.020
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Table 3.7. Number of CpG sites in DMRs with BPM, PL, and DC
Method
BMP
PL
DC

Number of
DMRs
277
1
492

Mean of
Number of CpGs
11.671
31
11.376

Standard Deviation of
Number of CpGs
4.300
0
5.465

Figure 3.2. Width of the DMRs found with BMP and DC

Figure 3.3. Chromosomes of the DMRs found with BMP and DC
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Figure 3.4. Number of CpGs for each of the DMRs found with BMP and DC

Table 3.8. Percentage overlaps between BMP, PL, and DC
Comparison
BMP vs
PL
PL vs
DC
BMP vs
DC

Number of
Overlaps

Mean of
Percentage of Overlap

Standard Deviation of
Percentage Overlap

1

1

0

1

1

0

233

0.949

0.128

Figure 3.5. Percentage of overlap between BMP and DC
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3.4. COMPARING BMP, PL-BMP, DC-BMP
The next comparison of interest is to investigate results when DMRcate and Probe
Lasso have altered parameters to achieve the same number of DMRs (277) as Bumphunter
default settings. When parameters were changed for both DC-BMP and PL-BMP, then
277 and 276 DMRs, respectively, were found. When the FDR parameter for DC-BMP was
reduced in value, the number of significant sites to be used in DMRs was also decreased
due to a more stringent inclusion threshold. This resulted in a reduction in DMRs. When
PL-BMP parameters of MeanLassoRadius was increased in value, this created a larger area
around sites deemed significant to have lassos. This resulted in more CpG sites within
each lasso, and the sizes of DMRs growing. When AdjPvalProbe was increased, then the
significance threshold used to determine which sites to fall within each lasso increased and
thus made less stringent. This resulted in more sites being able to be collected with each
lasso. With all three methods identifying similar numbers of DMRs, a comparison of the
DMRs identified between the methods can be conducted. The width statistics given in
Table 3.9 and Figure 3.6 reveal that the widths of DMRs between BMP and DC-BMP are
similar, whereas PL-BMP is drastically different in both average and standard deviation.
From Table 3.10 and Figure 3.7, all three methods have different mode values for locations
of DMRs. The number of CpGs in the DMRs from BMP and DC-BMP are similar, as
seen in Table 3.11 and Figure 3.8, but PL-BMP has both a higher average and variation
in CpG density. Lastly, when examining the overlaps between methods in Table 3.12 and
Figure 3.9, the highest total number of overlaps between two methods was found between
BMP and DC-BMP (176). While the comparisons of BMP with PL-BMP, and PL-BMP
with DC-BMP showed comparable numbers of overlaps (101 and 110, respectively), the
PL-BMP and DC-BMP methods appear to have a much higher average of the percentage
overlap (69.98% compared to 33.81%).
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Table 3.9. Width of DMRs with BMP, PL-BMP, and DC-BMP
Method
BMP
PL-BMP
DC-BMP

Number
of DMRs
277
277
276

Average
Width of DMRs
1175.018
9820.430
1163.442

Standard Deviation
of Width of DMRs
634.300
8135.753
615.362

Table 3.10. Chromosome of DMRs with BMP, PL-BMP, and DC-BMP
Method
BMP
PL-BMP
DC-BMP

Number
of DMRs
277
277
276

Mode of
Chromosomes of DMRs
1.000
6.000
11.000

Standard Deviation
of Chromosome of DMRs
5.832
5.609
6.019

Table 3.11. Number of CpG sites in DMRs with BMP, PL-BMP, and DC-BMP
Method
BMP
PL-BMP
DC-BMP

Number of
DMRs
277
277
276

Mean of
Number of CpGs
11.671
26.361
11.384

Standard Deviation of
Number of CpGs
4.300
30.882
5.334

Figure 3.6. Width of the DMRs found with BMP, PL-BMP, and DC-BMP
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Figure 3.7. Chromosomes of the DMRs found with BMP, PL-BMP, and DC-BMP

Figure 3.8. Number of CpGs in the DMRs found with BMP, PL-BMP, and DC-BMP
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Table 3.12. Percentage overlaps between BMP, PL-BMP, and DC-BMP
Comparison
BMP vs
PL-BMP
PL-BMP vs
DC-BMP
BMP vs
DC-BMP

Number of
Overlaps

Mean of
Percentage of Overlap

Standard Deviation of
Percentage Overlap

101

0.338

0.334

110

0.700

0.311

176

0.689

0.282

Figure 3.9. Percentage of overlap between BMP, PL-BMP, and DC-BMP
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3.5. COMPARING BMP-PL, PL, DC-PL
In this comparison, the parameters of BMP-PL and DC-PL were changed so that
each test produced only one DMR as significant in order to compare to the PL default
results. When the MaxGap parameter of BMP-PL decreased, the distance between sites
to be considered part of the same DMR became smaller. This resulted in less sites being
grouped together and decreasing the number of DMRs found. The parameters of DC-PL
were changed to reduce the number of DMRs and in the same manner as discussed earlier
with DC-BMP. The results for PL, BMP-PL, and DC-PL were compared for the single DMR
found with the three methods. When looking at the widths of the DMRs found with these
methods, Table 3.13 shows that PL and DC-PL appear to have similar width while BMP-PL
is a significantly shorter DMR. As seen in Table 3.14, all three methods identified a DMR
that was located on Chromosome 6. Once again, PL and DC-PL have similar number of
CpGs in their DMRs as seen in Table 3.15. There was only a single overlap of DMRs
between any of the tests. From Table 3.16, the percentage of the single overlap between PL
and DC-PL was 82.68%.
Table 3.13. Width of DMRs with PL, BMP-PL, and DC-PL
Method
BMP-PL
PL
DC-PL

Number
of DMRs
1
1
1

Average
Width of DMRs
33
654
791

Standard Deviation
of Width of DMRs
0
0
0

Table 3.14. Chromosome of DMRs with PL, BMP-PL, and DC-PL
Method
BMP-PL
PL
DC-PL

Number
of DMRs
1
1
1

Mode of
Chromosomes of DMRs
6
6
6

Standard Deviation
of Chromosome of DMRs
0
0
0
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Table 3.15. Number of CpG sites in DMRs with PL, BMP-PL, and DC-PL
Method
BMP-PL
PL
DC-PL

Number of
DMRs
1
1
1

Mean of
Number of CpGs
9
31
28

Standard Deviation of
Number of CpGs
0
0
0

Table 3.16. Percentage overlaps between PL, BMP-PL, and DC-PL
Comparison
BMP-PL vs
PL
PL vs
DC-PL
BMP-PL vs
DC-PL

Number of
Overlaps

Mean of
Percentage of Overlap

Standard Deviation of
Percentage Overlap

0

0

0

1

0.827

0

0

0

0

3.6. COMPARING BMP-DC, PL-DC, DC
When the parameters for DC were left at default except for the number of cores
being 1, the two tests of BMP-DC and PL-DC had their parameters changed to also reflect a
similar number of identified DMRs. When BMP-DC had the parameter MaxGap increased
in value, this made the distance between sites to be considered part of the same DMR to
be greater. This resulted in more CpG sites to be clustered together and a increase in the
number of DMRs found from this method0. When the parameters for PL-DC were changed
to increase the number of DMRs, it created a similar effect as discussed earlier for PL-BMP.
From Table 3.17 and Figure 3.10, DC was able to identify 492 DMRs with its default
parameters, while BMP-DC and PL-DC identified 494 and 490 respectively. Both average
and standard deviation for the widths were drastically different when comparing either of
BMP-DC or DC to PL-DC. PL-DC on average identified DMRs that were more then ten
times as large as either of the other methods. The chromosome that the DMRs were found
on are similar for all three tests. The Table 3.18 and Figure 3.11 shows that all three tests
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have similar mode value for the DMRs with Chromosome 1. When the number of CpGs
per DMR was examined, PL-DC stood out, as seen with Table 3.19 and Figure 3.12, with
on average having more than twice the amount of CpGs then either BMP-DC or DC. Lastly,
when percentage of overlaps between tests was examined in Table 3.20 and Figure 3.13,
the most number of overlaps was between BMP-DC and DC. This pair also exhibited the
highest average of percentage overlap and the lowest standard deviation than the other two
comparisons.
Table 3.17. Width of DMRs with DC, BMP-DC, and PL-DC

Method
BMP-DC
PL-DC
DC

Number
of DMRs
494
490
492

Average
Width of DMRs
1245.393
16626.730
1363.980

Standard Deviation
of Width of DMRs
736.602
13471.940
769.245

Table 3.18. Chromosome of DMRs with DC, BMP-DC, and PL-DC

Method
BMP-DC
PL-DC
DC

Number
of DMRs
494
490
492

Mode of
Chromosomes of DMRs
1.000
1.000
1.000

Standard Deviation
of Chromosome of DMRs
5.852
5.609
6.020

Table 3.19. Number of CpG sites in DMRs with DC, BMP-DC, and PL-DC

Method
BMP-DC
PL-DC
DC

Number of
DMRs
494
490
492

Mean of
Number of CpGs
12.130
29.308
11.376

Standard Deviation of
Number of CpGs
4.976
43.442
5.465
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Figure 3.10. Width of the DMRs found with DC, BMP-DC, and PL-DC

Figure 3.11. Chromosomes of the DMRs found with DC, BMP-DC, and PL-DC
Table 3.20. Percentage overlaps between DC, BMP-DC, and PL-DC
Comparison
BMP-DC vs
PL-DC
PL-DC vs
DC
BMP-DC vs
DC

Number of
Overlaps

Mean of
Percentage of Overlap

Standard Deviation of
Percentage Overlap

241

0.279

0.320

256

0.284

0.314

355

0.892

0.171
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Figure 3.12. Number of CpGs in the DMRs found with DC, BMP-DC, and PL-DC

Figure 3.13. Percentage of overlap between DC, BMP-DC, and PL-DC
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4. CONCLUSIONS

4.1. SUMMARY
DNA methylation data from a 2013 cervical cancer study was analyzed with the
use of the R package,"ChAMP," to find potentially significant DMRs within the genome.
With the use of three methods for identifying DMRs ("Bumphunter," "Probe Lasso," and
"DMRcate"), DMRs were found when comparing a group of eight HIV positive women
with Squamous Cell Carcinoma (SCC) cervical cancer to a group of five HIV positive
women with no cervical cancer. The overall conclusion that can be drawn from the final
results is that the three methods produced different results. In addition to the differences in
DMRs, the outputs that each method produces was also different. While all three reported
the Start, End, and Chromosome on which each DMR was located, DMRcate also reported
both the gene that each DMR was a part of and how many CpG sites each DMR contained.
Probe Lasso reported the genes associated with the DMRs, but did not give the number of
CpG sites. Bumphunter reported neither of these pieces of information. Both the number
of CpGs and gene association are useful to know when examining what type of DMRs are
being reported and possible relationships the DMRs might have with the expression of the
genes. If either of these pieces of information are missing then it can be done manually
instead of through a known function or package. This method is prone to being both
time intensive and mistake prone. Improvements to both Bumphunter’s and Probe Lasso’s
packages are desirable in the future to counter these limitations.
When examining the analyzed results, throughout all nine analyses conducted involving Bumphunter, Probe Lasso, and DMRcate, both DMRcate and Bumphunter produce
somewhat similar results as seen with the amount of percentage overlaps between DMRs
identified with the two methods. They also showed similar means and standard deviations
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with the DMRs’ widths, Chromosome location, and number of CpGs. The only radical
difference is the number of DMRs found in both methods with default parameters. The 492
DMRs found with DMRcate was more than 1.5 times larger than the 277 DMRs found with
Bumphunter. The default parameters for all three methods produce vastly different number
of identified DMRs with Probe Lasso finding only one DMR. To get a comparable number
of DMRs among the three methods, the parameters of each method had to be changed.
When Bumphunter and DMRcate are able to find a similar number of DMRs, the number
of DMRs in common to both methods and percentage overlap of those DMRs are relatively
high. When comparing all three methods, Probe Lasso was usually an outlier. The widths
and number of CpG sites for each DMR was significantly larger for Probe Lasso than either
of the other two tests. There could be many contributing factors to this outcome. One
cause could be the drastic increase in the significance threshold for probes to be considered
part of the DMRs created with Probe Lasso. By increasing this value, the method was
least stringent and accepted probes into DMRs that would normally not be accepted with
either Bumphunter or DMRcate. Another factor in the inability of Probe Lasso to identify
multiple DMRs under the default setting, could be the type of microarray used. Since Probe
Lasso is based on meeting a minimum number of significant CpG sites to be considered
part of a DMR, then increasing the total number of probes could potentially allow more
DMRs to be identified. This would mean that the use of EPIC might encourage a better
identification of DMRs than 450K with Probe Lasso.
When looking at the results, an important piece of information that needs to be
considered with DMRs is the gene with which the DMR is associated. If the DMR is
part of a gene or its transcription factor start site, this could affect how the gene will be
expressed and the outcome produced when this happens. Thus, both Probe Lasso and
DMRcate are advantageous in that any genes associated with each DMR are reported in
their results. Bumphunter does not report this information and, if desired, this information
must be obtained manually, which was completed for this thesis. Genes for the top five
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best DMRs for all nine analyses were found. Bumphunter’s DMRs are ranked based on the
pvaluearea, Probe Lasso are ranked with dmrP, and DMRcate does not report the p-values
used for obtaining the DMRS in the results for the researcher. However, DMRcate does rank
the DMRs from the lowest p-value to highest and provides the ranking for the researcher.
Table 4.1 provides the gene associations for any DMR found in the top five in any of
the nine analyses. The table contains columns that include the gene name, which method
found this gene, and any possible association between these genes to diseases and body
functions. The associations was obtained through the Database of RefSeqGene [30]. This
database is a collection from various researchers that have found connections between genes
and diseases. With this database specific genes can be looked up and the diseases can be
found. For example the SALL1 gene had associated DMRs with the methods of BMPDC, DC, DC-BMP, and PL-DC. From RefSeqGene, SALL1 is linked with protein coding
and has known connections to Townes-Brocks syndrome and Bronchio-oto-renal syndrome
whenever the gene contains defects [30]. With this information, a researcher will have a
better idea of how the DMRs located in genes might be linked to diseases.

4.2. FUTURE/DISCUSSION
Even though comparisons between the three methods could be made from the
results, the answer of which method with what parameters would most effective at correctly
identifying the DMRs cannot be determined since it is unknown where the true DMRs
are located. Thus, the amount of Type 1 and Type 2 errors for the nine different analyses
could not be calculated and there was no way to find these pieces of information without
knowing the true DMRs. To be able to gather this information, a simulation study would be
necessary. There are no existing public codes or packages that would let a user to do this.
Thus, a new and original code would have to be made. So in the future, to help answer what
method would be best, a code to create a simulation study that examined different possible
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scenarios would have to be made. Then, different parameter settings could be more fully
investigated to learn which methods and parameters perform well in different scenarios.
This could help inform researchers on the most suitable method to use for their data.
Another issue that was found was the drastically different results that Probe Lasso
found when compared to either of the two other methods. For example, the default parameters for this method were only able to find one DMR from the data. A possible solution
to this might be the type of microarray that is used to gather the data. If EPIC was used
then there would be nearly double the number of probes on the array. Since Probe Lasso
is significantly dependent on identifying clusters and high concentrations of probes that are
showing differences in methylation, an increase to probes used in testing samples might
improve in the ability to find DMRs. If possible, a comparison could be made on the DMRs
found with Probe Lasso when the samples were taken with 450K and EPIC microarrays.
Also, as discussed earlier, when the parameters for Probe Lasso were changed to identify
more DMRs, the DMRs found were outliers when compared to either Bumphunter or DMRcate. One possible avenue to correct this with Probe Lasso would be to explore how
changing other parameters might effect the DMRs found. Changing other parameters might
produce more comparable DMRs with Probe Lasso to either Bumphunter or DMRcate.
Another important issue was the difference in the number of DMRs found with
Bumphunter and DMRcate when both tests used their default parameters. Even though
there were considerable overlaps between the DMRs from Bumphunter and DMRcate,
DMRcate still identified more DMRs. Further investigation needs to be done to determine
if this difference exists with larger number of samples. If so, then knowing a possible way
to determine what parameters to change in order for a researcher to be able to get similar
results from both tests may be informative. Overall, further investigation is needed to better
understand the difference in performance of the methods under different parameter settings.
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Table 4.1. Gene and known associations for top five DMRs identified in any of the nine
analyses.
Gene Name
EDNRB

OR2I1P

EYA4
ELMO1
SALL1

ADCYAP1
GFRA1
PAX6

RP11

Methods
BMP,
BMP-DC,
DC-BMP
BMP,
BMP-DC,
DC,
DC-PL,
DC-BMP,
PL
BMP,
BMP-PL,
BMP-DC,
PL-BMP
BMP
BMP-DC,
DC,
DC-BMP,
PL-DC
BMP-DC,
DC
DC,
DC-BMP
DC,
DC-BMP,
PL-DC
DC,
PL-DC,
PL-BMP

ZIC4

PL-DC

ZIC1

PL-DC
PL-DC,
PL-BMP
PL-DC,
PL-BMP
PL-BMP
PL-BMP

TRIM40
SNORD116
RIC3
TBX18

Association
Hirschsprung disease type 2

No known disease, Olfactory receptors

dilated cardiomyopathy 1J
glioma cell invasion, diabetic nephropathy
Townes-Brocks syndrome,
bronchio-oto-renal syndrome
multiple mature peptides
Hirschsprung disease
aniridia, Peter’s anomaly

No information through database
Dandy-Walker malformation,
X-linked visceral heterotaxy,
holoprosencephaly type 5
medulloblastoma
regulates inflammation and
carcinogenesis in the gastrointestinal tract
small nucleolar RNA, C/D box
encodes proteins to be resistant to inhibitors
Effects embryonic development
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However, by comparing the methods using the approach in this thesis, many conclusions
about the similarity and differences between the methods when applied to a real data set
could be made.
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APPENDIX

Table A1. Top 5 DMRs determined by p.valArea for BMP
DMR_3
DMR_1
DMR_4
DMR_10
DMR_2

seqnames
chr13
chr6
chr6
chr6
chr7

start
78492568
29521013
133561756
28602543
37488162

end
78494067
29521803
133562774
28603437
37488936

width
1499
790
1018
894
774

p.valueArea
5.01E-05
5.01E-05
0.000267032
0.000500684
0.000550753

Table A2. Top result for BMP-PL
DMR_1

seqnames
chr6

start
133562461

end
133562494

width
33

p.valueArea
0.041666667

Table A3. Top 5 results determined by p.valArea for BMP-DC
DMR_14
DMR_1
DMR_8
DMR_27
DMR_2

seqnames
chr16
chr6
chr13
chr6
chr18

start
51183988
29520698
78492568
133561614
904523

end
51190201
29521803
78494064
133564578
909154

width
6213
1105
1496
2964
4631

p.valueArea
4.31E-05
4.31E-05
5.17E-05
5.17E-05
0.000112123
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Table A4. Top 5 results determined by dmrP for PL-BMP
DMR_251
DMR_210
DMR_252

seqnames
chr6
chr6
chr6

start
85471060
30094504
133561581

end
85485442
30096205
133562614

width
14383
1702
1034

dmrP
3.02E-55
1.83E-44
1.00E-36

dmrpRank
1
2
3

DMR_104

chr15

25302950

25335070

32121

3.48E-29

4

DMR_56

chr11

8190225

8195246

5022

3.00E-24

5

ensemblID
ENSG00000112837
ENSG00000204614
ENSG00000112319
ENSG00000207014;
ENSG00000207464;
ENSG00000207191;
ENSG00000207442;
ENSG00000207133;
ENSG00000207093;
ENSG00000206727;
ENSG00000200661;
ENSG00000206609;
ENSG00000206193;
ENSG00000206621;
ENSG00000207174;
ENSG00000207263;
ENSG00000206656;
ENSG00000206688;
ENSG00000207460;
ENSG00000207236;
ENSG00000207159
ENSG00000166405;
ENSG00000246820

geneSymbol
TBX18
TRIM40
EYA4

SNORD116-3;
NA;SNORD116-5;
SNORD116-6;
SNORD116-7;
SNORD116-8;
SNORD116-9;
SNORD116-10;
SNORD116-11;
SNORD116-14;
NA;SNORD116-15;
SNORD116-16;
SNORD116-17;
SNORD116-18;
SNORD116-19

RIC3;
RP11-379P15.1

Table A5. Top result determined with dmrP for PL
DMR_1

seqnames
chr6

start
29521136

end
29521789

width
654

dmrP
3.32E-138

dmrpRank
1

ensemblID
ENSG00000237988

geneSymbol
OR2I1P

Table A6. Top 5 results determined by dmrP for PL-DC
DMR_214

seqnames
chr16

start
51184983

end
51211725

width
26743

dmrP
2.62E-52

dmrpRank
1

DMR_310

chr3

147075348

147128550

53203

1.82E-44

2

DMR_392

chr6

30094265

30096485

2221

2.09E-44

3

DMR_190

chr15

25289307

25344324

55018

1.82E-37

4

DMR_110

chr11

31825004

31828505

3502

1.64E-35

5

ensemblID
ENSG00000103449
ENSG00000243620;
ENSG00000174963;
ENSG00000241202;
ENSG00000152977
ENSG00000204614
ENSG00000207063;
ENSG00000207001;
ENSG00000207014;
ENSG00000207464;
ENSG00000207191;
ENSG00000207442;
ENSG00000207133;
ENSG00000207093;
ENSG00000206727;
ENSG00000200661;
ENSG00000206609;
ENSG00000206193;
ENSG00000206621;
ENSG00000207174;
ENSG00000207263;
ENSG00000206656;
ENSG00000206688;
ENSG00000207460;
ENSG00000207236;
ENSG00000207159;
ENSG00000207375;
ENSG00000207279
ENSG00000007372

geneSymbol
SALL1
RP11-649A16.1;
ZIC4;ZIC4-AS1;
ZIC1
TRIM40

SNORD116-1;
SNORD116-2;
SNORD116-3;
NA;SNORD116-5;
SNORD116-6;
SNORD116-7;
SNORD116-8;
SNORD116-9;
SNORD116-10;
SNORD116-11;
SNORD116-14;
NA;SNORD116-15;
SNORD116-16;
SNORD116-17;
SNORD116-18;
SNORD116-19;
SNORD116-23;
SNORD116-24

PAX6
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Table A7. Top 5 results ranked for DC-BMP
seqnames

start

end

width

no.cpgs

Stouffer

DMR_1

chr6

29520527

29521803

1277

30

4.30E-38

DMR_2

chr16

51183988

51188129

4142

29

1.73E-26

DMR_3

chr10

118030848

118034031

3184

22

1.02E-20

DMR_4

chr11

31824973

31828040

3068

19

2.98E-16

DMR_5

chr13

78492216

78494462

2247

42

9.85E-16

overlapping.promoters
OR2I1P-201;
OR2I1P-001
SALL1-001;
SALL1-201;
SALL1-202;
SALL1-005;
SALL1-002;
AC009166.5-001;
SALL1-003
GFRA1-002;
GFRA1-003;
GFRA1-001;
GFRA1-201;
GFRA1-004
PAX6-016;
PAX6-006;
PAX6-014;
PAX6-015;
PAX6-007;
PAX6-025;
PAX6-029;
PAX6-024;
PAX6-026
EDNRB-003;
EDNRB-001;
EDNRB-201;
EDNRB-002;
RNF219-AS1-013

Table A8. Top result ranked for DC-PL
DMR_1

seqnames

start

end

width

no.cpgs

Stouffer

chr6

29521013

29521803

791

28

3.74E-39

overlapping.promoters
OR2I1P-201;
OR2I1P-001
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Table A9. Top 5 results ranked for DC
seqnames

start

end

width

no.cpgs

Stouffer

DMR_1

chr6

29520527

29521803

1277

30

2.48E-38

DMR_2

chr16

51183988

51190201

6214

38

7.58E-29

DMR_3

chr10

118030848

118034357

3510

23

9.52E-20

DMR_4

chr18

904523

909154

4632

26

5.48E-19

DMR_5

chr11

31824327

31828715

4389

21

9.90E-17

overlapping.promoters
OR2I1P-201;
OR2I1P-001
SALL1-001;
SALL1-201;
SALL1-202;
SALL1-005;
SALL1-002;
AC009166.5-001;
SALL1-003
GFRA1-002;
GFRA1-003;
GFRA1-001;
GFRA1-201;
GFRA1-004
ADCYAP1-005;
ADCYAP1-002;
RP11-672L10.2-004;
ADCYAP1-003;
RP11-672L10.2-003;
ADCYAP1-004;
RP11-672L10.2-002;
RP11-672L10.3-001;
RP11-672L10.2-001
PAX6-016;
PAX6-006;
PAX6-014;
PAX6-015;
PAX6-007;
PAX6-025;
PAX6-027;
PAX6-029;
PAX6-024;
PAX6-026

53
REFERENCES

[1] Anthony JF Griffiths. An introduction to genetic analysis. Macmillan, 2005.
[2] Ruth Pidsley, Elena Zotenko, Timothy J Peters, Mitchell G Lawrence, Gail P Risbridger, Peter Molloy, Susan Van Djik, Beverly Muhlhausler, Clare Stirzaker, and
Susan J Clark. Critical evaluation of the illumina methylationepic beadchip microarray for whole-genome dna methylation profiling. Genome biology, 17(1):208, 2016.
[3] Andrew E Jaffe, Peter Murakami, Hwajin Lee, Jeffrey T Leek, M Daniele Fallin,
Andrew P Feinberg, and Rafael A Irizarry. Bump hunting to identify differentially
methylated regions in epigenetic epidemiology studies. International journal of epidemiology, 41(1):200–209, 2012.
[4] DJ Weisenberger, D Van Den Berg, F Pan, BP Berman, and PW Laird. Comprehensive
dna methylation analysis on the illumina infinium assay platform. Illumina, San Diego,
2008.
[5] Martin J Aryee, Andrew E Jaffe, Hector Corrada-Bravo, Christine Ladd-Acosta, Andrew P Feinberg, Kasper D Hansen, and Rafael A Irizarry. Minfi: a flexible and
comprehensive bioconductor package for the analysis of infinium dna methylation
microarrays. Bioinformatics, 30(10):1363–1369, 2014.
[6] Tiffany J Morris and Stephan Beck. Analysis pipelines and packages for infinium
humanmethylation450 beadchip (450k) data. Methods, 72:3–8, 2015.
[7] illumina.
Humanmethylation450 beadchip achieves breadth of coverage using two infinium chemistries.
Nucleic Acids Res, 2012.
[Online].
Available:
http://www.illumina.com/content/dam/illuminamarketing/documents/products/technotes/technote hm450 data analysis optimization.pdf. [Accessed October 2017].
[8] Sarah Dedeurwaerder, Matthieu Defrance, Emilie Calonne, Hélene Denis, Christos
Sotiriou, and François Fuks. Evaluation of the infinium methylation 450k technology.
Epigenomics, 3(6):771–784, 2011.
[9] Dongmei Li, Zidian Xie, Marc Le Pape, and Timothy Dye. An evaluation of statistical
methods for dna methylation microarray data analysis. BMC bioinformatics, 16(1):
217, 2015.
[10] Pan Du, Xiao Zhang, Chiang-Ching Huang, Nadereh Jafari, Warren A Kibbe, Lifang
Hou, and Simon M Lin. Comparison of beta-value and m-value methods for quantifying methylation levels by microarray analysis. BMC bioinformatics, 11(1):587,
2010.

54
[11] Juan Sandoval, Holger Heyn, Sebastian Moran, Jordi Serra-Musach, Miguel A Pujana,
Marina Bibikova, and Manel Esteller. Validation of a dna methylation microarray for
450,000 cpg sites in the human genome. Epigenetics, 6(6):692–702, 2011.
[12] Wanding Zhou, Peter W Laird, and Hui Shen. Comprehensive characterization,
annotation and innovative use of infinium dna methylation beadchip probes. Nucleic
acids research, 45(4):e22–e22, 2017.
[13] Jessica Nordlund, Christofer L Bäcklin, Per Wahlberg, Stephan Busche, Eva C
Berglund, Maija-Leena Eloranta, Trond Flaegstad, Erik Forestier, Britt-Marie Frost,
Arja Harila-Saari, et al. Genome-wide signatures of differential dna methylation in
pediatric acute lymphoblastic leukemia. Genome biology, 14(9):r105, 2013.
[14] Andrew E Teschendorff, Francesco Marabita, Matthias Lechner, Thomas Bartlett,
Jesper Tegner, David Gomez-Cabrero, and Stephan Beck. A beta-mixture quantile
normalization method for correcting probe design bias in illumina infinium 450 k dna
methylation data. Bioinformatics, 29(2):189–196, 2012.
[15] Michael H Kutner, Chris Nachtsheim, and John Neter. Applied linear regression
models. McGraw-Hill/Irwin, 2004.
[16] Timothy J Peters, Michael J Buckley, Aaron L Statham, Ruth Pidsley, Katherine
Samaras, Reginald V Lord, Susan J Clark, and Peter L Molloy. De novo identification
of differentially methylated regions in the human genome. Epigenetics & chromatin,
8(1):6, 2015.
[17] Yoav Benjamini and Yosef Hochberg. Controlling the false discovery rate: a practical
and powerful approach to multiple testing. Journal of the royal statistical society.
Series B (Methodological), pages 289–300, 1995.
[18] Gordon K Smyth. Limma: linear models for microarray data. In Bioinformatics and
computational biology solutions using R and Bioconductor, pages 397–420. Springer,
2005.
[19] Lee M Butcher and Stephan Beck. Probe lasso: a novel method to rope in differentially
methylated regions with 450k dna methylation data. Methods, 72:21–28, 2015.
[20] Samuel A Stouffer, Edward A Suchman, Leland C DeVinney, Shirley A Star, and
Robin M Williams Jr. The american soldier: Adjustment during army life.(studies in
social psychology in world war ii), vol. 1. 1949.
[21] Franklin E Satterthwaite. An approximate distribution of estimates of variance components. Biometrics bulletin, 2(6):110–114, 1946.
[22] Yuan Tian, Tiffany Morris, Lee Stirling, Andrew Feber, Andrew Teschendorff, Ankur
Chakravarthy, Maintainer Yuan Tian, and Block GUI. Package âĂŸchampâĂŹ. 2017.

55
[23] Jean-Philippe Fortin, Timothy J Triche Jr, and Kasper D Hansen. Preprocessing,
normalization and integration of the illumina humanmethylationepic array with minfi.
Bioinformatics, 33(4):558–560, 2016.
[24] Jovana Maksimovic, Lavinia Gordon, and Alicia Oshlack. Swan: Subset-quantile
within array normalization for illumina infinium humanmethylation450 beadchips.
Genome biology, 13(6):R44, 2012.
[25] James M Wettenhall and Gordon K Smyth. limmagui: a graphical user interface for
linear modeling of microarray data. Bioinformatics, 20(18):3705–3706, 2004.
[26] Gordon K Smyth. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Statistical applications in genetics and
molecular biology, 3(1):1–25, 2004.
[27] Rafael A Irizarry, Martin Aryee, Hector Corrada Bravo, Kasper D Hansen, Harris A Jaffee, Maintainer Rafael A Irizarry, Suggests RUnit, Epigenetics biocViews
DNAMethylation, and MultipleComparisons Infrastructure. Package âĂŸbumphunterâĂŹ. 2013.
[28] L Butcher and T Morris. Illumina450probevariants. db: annotation package combining
variant data from 1000 genomes project for illumina humanmethylation450 bead chip
probes. R package version, 1(0), 2013.
[29] Michael Lawrence, Wolfgang Huber, Hervé Pages, Patrick Aboyoun, Marc Carlson,
Robert Gentleman, Martin T Morgan, and Vincent J Carey. Software for computing
and annotating genomic ranges. PLoS computational biology, 9(8):e1003118, 2013.
[30] Brister JR Ciufo S Haddad D McVeigh R Rajput B Robbertse B Smith-White B AkoAdjei D Astashyn A Badretdin A Bao Y Blinkova O Brover V Chetvernin V Choi J
Cox E Ermolaeva O Farrell CM Goldfarb T Gupta T Haft D Hatcher E Hlavina W
Joardar VS Kodali VK Li W Maglott D Masterson P McGarvey KM Murphy MR
O’Neill K Pujar S Rangwala SH Rausch D Riddick LD Schoch C Shkeda A Storz
SS Sun H Thibaud-Nissen F Tolstoy I Tully RE Vatsan AR Wallin C Webb D Wu
W Landrum MJ Kimchi A Tatusova T DiCuccio M Kitts P Murphy TD Pruitt KD
O’Leary NA, Wright MW. Reference sequence (refseq) database at ncbi: current
status, taxonomic expansion, and functional annotation. Nucleic Acids Res, January
2016. 44(D1):D733-45.

56
VITA

In December 2012, Arnold Harder graduated from University of Alaska Anchorage
with a B.S. in Mathematics and a minor in Statistics. He received a Master of Science in
Applied Mathematics with a Statistics Emphasis from Missouri University of Science and
Technology in December 2017.

